Clinical trials of new treatments for Fragile X are accepting participants

Source: 
FRAXA Research Foundation
Date Published: 
March 22, 2012
Abstract: 

Experimental new drugs, AFQ056 (an mGluR5 antagonist from Novartis) and STX209 (arbaclofen from Seaside Therapeutics) are in large scale trials.